15:06 EDT OS Therapies (OSTX) CEO Paul Romness sees ‘huge upside potential’
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
- OS Therapies Raises $4.2M Through Warrant Exercise
- OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating
- OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program
- Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress
- OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2